Global Intragastric Balloons Market By Administration (Pill Form v/s Endoscopy), By Balloon Type (Single, Dual, Triple), By Filling Type (Saline Filled v/s Gas Filled), By Application (Obesity, Diabetes, Diet Control, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 86.27 Million
CAGR (2026-2031)	12.92%
Fastest Growing Segment	Saline Filled
Largest Market	North America
Market Size (2031)	USD 178.85 Million

Market Overview

The Global Intragastric Balloons Market will grow from USD 86.27 Million in 2025 to USD 178.85 Million by 2031 at a 12.92% CAGR. Intragastric balloons are temporary, minimally invasive medical devices inserted into the stomach to induce weight loss by occupying space and promoting early satiety. The market is primarily supported by the critical gap between conservative lifestyle modifications and invasive bariatric surgeries, alongside the escalating global burden of obesity which necessitates scalable therapeutic interventions. According to the World Obesity Federation, in 2024, projections indicated that the number of adults living with obesity globally will increase to 1.53 billion by 2035. This demographic pressure creates a sustained demand for non-surgical weight management solutions that offer a favorable risk profile compared to permanent surgical procedures.

However, a significant challenge impeding broader market expansion is the persistent concern regarding device safety and associated adverse events. Reports of complications such as spontaneous balloon hyperinflation, acute pancreatitis, and gastric perforation have led to heightened regulatory scrutiny and safety alerts, which can negatively impact patient confidence and adoption rates. Furthermore, the high procedural cost combined with inconsistent or limited reimbursement coverage by insurance payers acts as a financial barrier, restricting access for a large segment of the eligible patient population.

Key Market Drivers

The escalating global prevalence of obesity and overweight populations serves as the primary catalyst for the intragastric balloons market, creating an urgent need for effective weight management interventions that bridge the gap between conservative lifestyle modifications and invasive bariatric surgeries. As body mass index levels continue to rise worldwide, healthcare systems are increasingly adopting scalable, device-based therapies to mitigate the burden of obesity-related comorbidities. This demographic pressure is substantiated by recent surveillance; according to a report by KGOU, in December 2025, data from the Centers for Disease Control and Prevention indicated that in 2024, at least one in four adults in all U.S. states and territories had obesity, highlighting the pervasive nature of this public health crisis and the consequent demand for non-surgical therapeutic options.

Technological advancements in swallowable and adjustable balloon designs are further propelling market growth by addressing patient concerns regarding the invasiveness and risks associated with traditional endoscopic placement. The emergence of next-generation, pill-based delivery systems allows for procedure-less deployment, significantly enhancing patient compliance and expanding the addressable market to individuals seeking reversible, lower-risk solutions. This innovation has driven notable adoption in key regions; according to Allurion Technologies, in June 2025, the company reported that its B2B2C sales model demonstrated over 40% growth in Europe, reflecting strong consumer uptake of these advanced modalities. Additionally, the financial scale of this segment is evident, as according to Allurion Technologies, in March 2025, the company announced a full-year 2024 revenue of $32.1 million, underscoring the commercial viability and rising utilization of intragastric balloon technologies.

Download Free Sample Report

Key Market Challenges

The persistent concern regarding device safety and associated adverse events constitutes a significant barrier to the expansion of the global intragastric balloons market. Although these devices are intended to be minimally invasive, reports of serious complications such as spontaneous hyperinflation, acute pancreatitis, and gastric perforation have triggered heightened regulatory scrutiny. This scrutiny frequently results in safety alerts and mandatory product recalls, which directly erode patient confidence and discourage healthcare providers from recommending this therapeutic option. Consequently, the apprehension surrounding potential clinical risks outweighs the benefits for a large portion of the eligible patient population, leading to hesitancy in adoption and restricted market penetration.

The impact of these safety challenges is clearly reflected in recent procedural volumes, which show a marked contraction. According to the American Society for Metabolic and Bariatric Surgery, in 2023, the estimated number of intragastric balloon procedures performed in the United States declined to 1,461, a substantial drop from the 4,358 procedures recorded in the previous year. This sharp decrease underscores how safety-related apprehensions and the resulting cautiousness in clinical practice are effectively hampering market growth, preventing the technology from achieving the scale necessary to address the rising demand for non-surgical weight loss interventions.

Key Market Trends

The integration of AI-driven digital health ecosystems is reshaping the intragastric balloons market by shifting the focus to comprehensive care models. Manufacturers are increasingly bundling balloons with algorithmic coaching platforms that enable real-time tracking of physiological metrics, enhancing patient adherence and safety. This digital layer allows for personalized interventions that support critical clinical goals, such as the preservation of muscle tissue during weight reduction. The clinical value of this technology is evident; according to Allurion Technologies, May 2025, in a press release regarding data presented at the European Congress on Obesity, patients utilizing the company’s AI-powered Virtual Care Suite increased their lean body mass by an average of 6.1% over four months, validating the impact of digital adjuncts on treatment quality.

The emergence of combination therapies pairing intragastric balloons with GLP-1 receptor agonists is creating a new high-efficacy treatment paradigm within the sector. By leveraging the balloon's mechanical satiety, clinicians can utilize lower pharmaceutical dosages to mitigate drug-related side effects while amplifying overall weight loss. This synergistic protocol maximizes fat reduction and addresses the limitations of standalone pharmacotherapy, such as plateauing results. The potency of this strategy is significant; according to Allurion Technologies, November 2025, in a press release regarding its Smart Capsule and low-dose tirzepatide regimen, patients achieved an average total body weight loss of 23% after 12 months, a result significantly superior to historical outcomes for device-only interventions.

Segmental Insights

The Saline Filled segment is currently the fastest-growing category in the Global Intragastric Balloons Market, driven primarily by its superior clinical efficacy and robust safety profile. Unlike gas-filled options, saline balloons settle at the bottom of the stomach to effectively delay gastric emptying, often resulting in greater weight loss outcomes. Furthermore, these devices frequently incorporate safety mechanisms, such as methylene blue dye, which alerts patients to leakage, thereby facilitating timely medical intervention. Continued market authorization by the FDA for advanced saline systems reinforces this growth, as healthcare providers increasingly prioritize these reliable, evidence-based solutions for non-surgical obesity management.

Regional Insights

North America maintains a leading position in the global intragastric balloons market, driven primarily by the high prevalence of obesity and a strong preference for minimally invasive weight loss solutions. The region benefits from a developed healthcare infrastructure that facilitates widespread access to medical treatments. Additionally, the U.S. Food and Drug Administration (FDA) has granted approval for multiple balloon systems, which enhances provider confidence and accelerates product adoption. This regulatory support, combined with the presence of major medical device manufacturers, ensures that North America remains the primary revenue generator within the global landscape.

Recent Developments

• In August 2025, Allurion Technologies announced a new strategic direction focused on the development of a novel GLP-1 drug-eluting intragastric balloon. The company signed a term sheet with a strategic partner to collaborate on this innovative combination therapy, which aims to leverage the weight loss benefits of the gastric balloon while delivering anti-obesity medication directly to the stomach. This initiative was part of a broader shift towards combining device-based interventions with pharmaceutical treatments to optimize weight loss outcomes and preserve muscle mass. The announcement highlighted the company's effort to adapt to the evolving landscape of obesity management by integrating mechanical and pharmacological approaches.
• In August 2025, ReShape Lifesciences announced that its shareholders had approved a definitive merger agreement with Vyome Therapeutics, a clinical-stage healthcare company. Under the terms of the all-stock transaction, the combined entity was set to operate under a new name and trading symbol, focusing on immuno-inflammatory diseases while leveraging the U.S.-India innovation corridor. Concurrently, the company progressed with an asset purchase agreement to sell substantially all of its weight loss assets, including the Obalon Gastric Balloon System, to Biorad Medisys. This restructuring represented a major pivot for the company, effectively transitioning its primary focus away from the direct commercialization of its legacy medical devices in the weight loss sector.
• In December 2024, Boston Scientific Corporation expanded its footprint in the Asian market by launching the Orbera365 Intragastric Balloon System alongside the Apollo ESG System in India. This strategic move was aimed at addressing the growing prevalence of obesity in the region by offering minimally invasive, endoscopic solutions. The Orbera365 system, a silicone balloon designed to occupy space in the stomach and induce satiety, was introduced as a temporary weight loss aid for adults who had not achieved desired results through diet and exercise alone. The launch underscored the company's commitment to broadening access to its endobariatric portfolio following its acquisition of Apollo Endosurgery.
• In March 2024, Spatz Medical announced the commercial launch of the Spatz3 Adjustable Gastric Balloon in the United States, marking a significant development in the domestic intragastric balloons market. This device, recognized as the first of its kind to offer adjustability, allows healthcare providers to modify the balloon's volume while it remains in the stomach, thereby potentially extending the treatment period and improving patient tolerance. The launch followed successful clinical trials which demonstrated that the adjustable feature contributed to higher success rates and greater total body weight loss compared to non-adjustable alternatives. This introduction provided a new, customizable non-surgical weight loss option for patients in the US market.

Key Market Players

• Apollo Endosurgery, Inc.
• Allurion Technologies, Inc.
• Obalon Therapeutics, Inc.
• Medtronic plc
• GI Dynamics, Inc.
• Spatz Medical, Inc.
• Lexel Medical, Inc.
• Bariatric Solutions, Inc.
• Endogastric Solutions, Inc.
• Reshape Lifesciences, Inc.

By Administration	By Balloon Type	By Filling Type	By Application	By End User	By Region
Pill Form v/s Endoscopy	Single Dual Triple	Saline Filled v/s Gas Filled	Obesity Diabetes Diet Control Others	Hospitals & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intragastric Balloons Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intragastric Balloons Market, By Administration:

• Pill Form v/s Endoscopy

• Intragastric Balloons Market, By Balloon Type:

• Single
• Dual
• Triple

• Intragastric Balloons Market, By Filling Type:

• Saline Filled v/s Gas Filled

• Intragastric Balloons Market, By Application:

• Obesity
• Diabetes
• Diet Control
• Others

• Intragastric Balloons Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

• Intragastric Balloons Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE